Bladder cancer (BCa) is the ninth most common cancer worldwide and is diagnosed by transurethral resection of a bladder tumor (TURBT). TURBT is one the most frequently performed urologic procedures and has an overall complication rate of 4–6% that varies depending on the tumor size, surgeon experience, and gender of the patient (Hollenbeck et al., Cancer, 106: 1527–1535. https://doi.org/10.1002/cncr.21765 , 2006). The surgical objectives of TURBT are to remove all visible cancers and stage the tumor by biopsy of the detrusor muscle (Sharma et al., Am Fam Physician, 80: 717–723, 2009). Most complications of TURBT are often lower-grade (80% under grade II) (Gregg et al., Can J Urol, 23(2): 8198–8203, 2016) and include bleeding, infection, noninfective cystitis, and bladder perforation (Hollenbeck et al., Cancer, 106: 1527–1535. https://doi.org/10.1002/cncr.21765 , 2006). We describe the incidence, prevention, and management of these complications and also describe special considerations for female patients.